After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
NeoGenomics (NEO) has experienced a significant 22.8% decline over the past four weeks, but indicators suggest a potential trend reversal. Its Relative Strength Index (RSI) of 26.14 places it in oversold territory. Additionally, Wall Street analysts have shown strong agreement in raising earnings estimates for the current year, and the stock holds a Zacks Rank #2 (Buy).
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
NeoGenomics, Inc. announced that its Chairman and Chief Executive Officer, Douglas VanOort, and Chief Strategy and Corporate Development Officer, Doug Brown, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021, at 11:00 am ET. The presentation will be webcast live on the investors section of the company's website. NeoGenomics specializes in cancer genetics testing and serves both physicians and pharmaceutical clients globally.
Why NeoGenomics (NEO) Shares Are Falling Today
Shares of NeoGenomics (NEO) fell over 10% after the oncology diagnostics company reported fourth-quarter results that beat expectations but issued a full-year 2026 forecast falling short of analyst predictions. Despite an 11% revenue growth in Q4 2025, the increased net loss for the full year 2025 and lower-than-anticipated 2026 guidance led to a negative market reaction. The company's stock has been highly volatile, with significant drops in the past year, and is currently trading 22.6% below its 52-week high.
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026
UBS reiterated a Hold rating on NeoGenomics, Inc. (NEO) on February 18, 2026, without issuing a new price target. Following this, NEO experienced a short-term pullback of -1.54%. The maintenance of a "Hold" rating suggests UBS views NeoGenomics as fairly valued among its peers, prompting investors to monitor fundamentals rather than making abrupt changes. Meyka AI independently rates NEO with a grade of B, factoring in various financial and market performance metrics.
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure
NeoGenomics Inc. (NEO) is facing significant risks related to the reliability and quality of its diagnostic tests, which could damage its reputation, reduce demand, and lead to legal claims. Inaccurate results or misinterpretations can result in costly litigation and regulatory scrutiny, impacting brand and client relationships. Despite these risks, Wall Street maintains a "Moderate Buy" consensus rating for NEO stock based on analyst recommendations.
NeoGenomics (NEO) Stock Drops After 2026 Outlook Misses Expectations - News and Statistics
NeoGenomics (NEO) stock declined over 10% after its 2026 financial forecast, including adjusted earnings per share and adjusted EBITDA, fell short of analyst expectations, overshadowing strong fourth-quarter revenue growth. The company reported a net loss of $108 million for full-year 2025, a 37% increase, and its stock has been highly volatile, down 13% since the start of 2026. This performance underscores the market's negative reaction to the weaker outlook despite positive quarterly revenue figures.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) reported its Q4 and full-year 2025 financial results, with Q4 revenue reaching $190 million, an 11% year-over-year increase, and full-year revenue at $727 million, up 10% from 2024. The company highlighted strong growth in its clinical business and NGS revenues, driven by strategic market penetration and new product launches like RADAR ST and PANTRACER. NeoGenomics provided 2026 revenue guidance between $793 million and $801 million, anticipating continued focus on high-value tests and improved operational efficiencies.
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. (NASDAQ: NEO) has announced its participation in two upcoming investor conferences: the 17th Annual Healthcare Conference in Boston on March 3rd and the Leerink Global Healthcare Conference in Miami on March 10th. The company, a leading provider of oncology diagnostic solutions, will conduct fireside chats at both events. Live and archived webcasts of the sessions will be available on NeoGenomics' investor relations website.
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3rd and the Leerink Global Healthcare Conference on March 10th. The company, a leading provider of oncology diagnostic solutions, will conduct fireside chats at both events. Live and archived webcasts will be available on NeoGenomics' investor relations website.
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook
NeoGenomics (NEO) reported Q4 CY2025 results that exceeded revenue and non-GAAP EPS expectations, driven by growth in next-generation sequencing (NGS) and a shift to higher-value testing. Despite strong operational performance and strategic investments, the market reacted negatively due to guidance that was mixed compared to analyst estimates, with EBITDA guidance slightly below expectations. The company plans further expansion in its product offerings and commercial reach, focusing on new product launches like RADAR ST and PANTRASER, alongside continued efforts for margin improvement.
NeoGenomics shares fall over 5% despite earnings beat
NeoGenomics Inc. (NASDAQ:NEO) reported fourth-quarter earnings and revenue that surpassed analyst expectations, yet its shares fell over 5% in pre-market trading, indicating investor concern about future growth. The cancer diagnostics provider achieved double-digit revenue growth driven by clinical volumes and a shift towards higher-value tests. For 2026, the company projected revenue in line with consensus but expects a net loss, while also highlighting the upcoming launch of a new assay targeting the molecular residual disease monitoring market.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics announced strong financial results for the fourth quarter and full year 2025, with full-year revenue growing 10% to $727 million and fourth-quarter consolidated revenue increasing 11% to $190 million. The company highlighted double-digit revenue growth driven by clinical volumes and a shift towards higher-value tests, particularly NGS, and provided positive financial guidance for 2026, projecting further revenue and adjusted EBITDA growth. A key focus for future growth is the imminent launch of their RaDaR ST MRD assay, targeting the significant molecular residual disease monitoring market.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics announced its fourth quarter and full-year 2025 results, reporting double-digit revenue growth driven by clinical volumes and a shift towards higher-value tests like NGS. Despite an increased net loss for the full year, the company achieved positive adjusted EBITDA and successfully resolved patent litigation. NeoGenomics also provided its 2026 financial guidance, projecting continued revenue and adjusted EBITDA growth, and highlighted the upcoming launch of its RaDaR ST MRD assay for the molecular residual disease monitoring market.
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript
NeoGenomics (NEO) reported strong Q4 2025 results with an 11% year-over-year revenue growth, driven by clinical segment expansion and a strategic shift towards higher-margin testing. The company is poised for further growth in 2026 with the launch of RADAR ST and PANTRACER LBX, alongside continued investments in sales, R&D, and operational efficiency, despite short-term headwinds in nonclinical revenue and clinical test volumes due to extreme weather and strategic client rationalization. Management expressed confidence in achieving their 2026 financial guidance, anticipating significant gross margin and Adjusted EBITDA expansion.
NEOGENOMICS ($NEO) Releases Q4 2025 Earnings
NEOGENOMICS ($NEO) reported strong Q4 2025 earnings, surpassing both earnings per share and revenue estimates. The article also provides detailed financial insights, including insider trading activity, significant hedge fund movements, government contracts awarded, and recent analyst ratings and price targets for the stock. This information suggests a positive outlook from analysts despite some insider selling.
NeoGenomics: Q4 Earnings Snapshot
NeoGenomics Inc. (NEO) reported a fourth-quarter loss of $9.9 million, or 8 cents per share, which adjusted to 6 cents per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts, posting $190.2 million for the period. For the full year, NeoGenomics reported a loss of $108 million on revenues of $727.3 million and projects 2026 full-year revenue between $793 million and $801 million.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics, Inc. announced its financial results for the fourth quarter and full year 2025, reporting a 10% increase in full-year revenue to $727 million and 11% increase in fourth-quarter consolidated revenue to $190 million. The company's clinical revenue grew by 15% for the full year, driven by higher-value tests including NGS. NeoGenomics also provided its financial guidance for 2026, projecting consolidated revenue between $793 million and $801 million, reflecting a 9-10% year-over-year increase.
Earnings Flash (NEO) NeoGenomics, Inc. Reports Q4 Revenue $190.2M, vs. FactSet Est of $188.5M
NeoGenomics, Inc. (NEO) announced its Q4 revenue for 2025 reached $190.2 million, surpassing the FactSet estimate of $188.5 million. The company also reported Q4 adjusted EPS of $0.06 per share, exceeding the FactSet estimate of $0.04. Furthermore, NeoGenomics provided full-year 2026 revenue guidance in the range of $793 million to $801 million, with the FactSet estimate at $796.6 million.
NeoGenomics: Q4 Earnings Snapshot
NeoGenomics Inc. (NEO) reported a fourth-quarter loss of $9.9 million, or 8 cents per share, which exceeded Wall Street expectations when adjusted for certain costs, resulting in earnings of 6 cents per share. The company's revenue of $190.2 million also surpassed forecasts. For the full year, NeoGenomics reported a loss of $108 million on revenue of $727.3 million and projects future revenue in the range of $793 million to $801 million.
NeoGenomics: Fourth Quarter Earnings Overview
NeoGenomics Inc. reported a net loss of $9.9 million for the fourth quarter, or 8 cents per share, with adjusted earnings of 6 cents per share, exceeding analyst expectations. The cancer diagnostic testing specialist generated $190.2 million in revenue for the quarter, surpassing average estimates. For the full year, the company had a total loss of $108 million on revenues of $727.3 million, and projects full-year revenue to be between $793 million and $801 million.
NeoGenomics earnings in the spotlight as analysts eye profitability
NeoGenomics Inc. is set to report its fourth-quarter results, with analysts focusing on the company's ability to drive profitability alongside revenue growth. The stock has seen significant gains from its 52-week low, but its high forward P/E ratio indicates that investors expect substantial profit growth. Key areas of interest include the impact of its Pathline acquisition and the performance of its advanced cancer diagnostic assays in less-penetrated markets.
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
NeoGenomics has launched PanTracer Pro, a new pan-solid tumor assay designed to simplify molecular testing for clinicians and help in making informed treatment decisions for patients with advanced solid tumors. This assay combines broad DNA and RNA sequencing with tumor-specific ancillary testing, aiming to reduce diagnostic complexity and turnaround time. The company anticipates this new offering will contribute to continued double-digit sales growth in 2026, building on previous revenue uptrends.
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
NeoGenomics has launched PanTracer Pro, a new pan-solid tumor assay designed to streamline molecular testing for advanced-stage solid tumors. This assay combines broad DNA and RNA sequencing with tumor-specific ancillary testing to aid in therapy selection and personalized treatment planning, reducing diagnostic complexity and turnaround time. The company’s shares saw an increase following the announcement, reflecting continued growth in its precision oncology initiatives.
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
NeoGenomics (NEO) has launched PanTracer Pro, a new pan-solid tumor assay aimed at simplifying molecular testing for advanced-stage solid tumor patients, enabling quicker, informed treatment decisions. This assay integrates broad DNA and RNA sequencing with tumor-specific ancillary testing, providing comprehensive insights within an 8-10 day turnaround time. The company's shares rose following the announcement, reflecting its continued growth in precision oncology.
NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance
NeoGenomics (NasdaqCM:NEO) has launched PanTracer Pro, a new diagnostic solution for advanced solid tumor treatment designed to streamline testing and improve biomarker assessment. Despite this innovation, the company has experienced significant share price declines over the past month, year, and five years. Investors will be monitoring the adoption rates of PanTracer Pro and its impact on the company's profitability, given that NeoGenomics is currently operating at a loss.
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For
NeoGenomics (NEO) is set to release its Q4 earnings report this Tuesday. Analysts anticipate a 9.5% year-on-year revenue growth to $188.3 million and adjusted earnings of $0.04 per share. The company has a history of missing Wall Street revenue estimates, and its stock has underperformed peers in the healthcare providers & services segment recently.
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For
NeoGenomics (NEO) is set to announce its Q4 earnings results. Analysts expect revenue growth of 9.5% year-on-year to $188.3 million and adjusted earnings of $0.04 per share. The company has a history of missing Wall Street's revenue estimates and its shares have underperformed the healthcare sector recently.
How (NEO) Movements Inform Risk Allocation Models
This article analyzes Neogenomics Inc. (NYSE: NEO) using AI models, highlighting a mid-channel oscillation pattern and divergent sentiment across various time horizons. It provides specific institutional trading strategies including position, momentum breakout, and risk hedging, along with detailed entry, target, and stop-loss levels. The analysis emphasizes an exceptional 78.3:1 risk-reward setup, targeting a 21.4% gain against a 0.3% risk.
NeoGenomics launches PanTracer Pro for advanced-stage solid tumors
NeoGenomics has introduced PanTracer Pro, a new molecular testing tool aimed at improving treatment decisions for patients with advanced-stage solid tumors. This solution seeks to streamline complex workflows in personalized oncology. The launch addresses a significant need in providing clinicians with essential information for tailored cancer treatments.
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
NeoGenomics has launched PanTracer Pro, a new diagnostic tool designed to streamline molecular testing for advanced-stage solid tumors. This integrated approach combines comprehensive genomic profiling with diagnosis-directed immunohistochemistry, aiming to provide earlier biomarker insights and reduce diagnostic uncertainty. PanTracer Pro helps clinicians make more informed treatment decisions, offering an 8-10 day turnaround time and the ability to reflex to liquid biopsy if tissue samples are insufficient.
NeoGenomics (NEO) Projected to Post Quarterly Earnings on Tuesday
NeoGenomics (NASDAQ: NEO) is anticipated to release its Q4 2025 earnings before market open on Tuesday, February 17th. Analysts project earnings of $0.04 per share on revenue of $188.25 million. The company's stock currently has a "Hold" consensus rating and a target price of $12.00, despite recent insider selling by the COO and EVP.
Trading Systems Reacting to (NEO) Volatility
This article from Stock Traders Daily discusses Neogenomics Inc. (NYSE: NEO) volatility, highlighting divergent sentiment across all time horizons and suggesting choppy conditions. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and risk-reward ratios for potential trades. The analysis indicates an exceptional 63.0:1 risk-reward short setup targeting a 19.1% downside.
165,890 Shares in NeoGenomics, Inc. $NEO Purchased by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd recently acquired 165,890 shares of NeoGenomics (NASDAQ:NEO) during Q3, a new stake valued at approximately $1.28 million, representing 0.13% of the company. Institutional ownership of NeoGenomics stands at about 98.50%, with several institutions increasing their holdings, while company insiders have sold shares. Analysts currently rate NeoGenomics as a "Hold" with an average price target of $12.00.
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Analysts
NeoGenomics, Inc. (NASDAQ:NEO) has received an average "Hold" recommendation from thirteen analysts, with an average 12-month price target of $12.00. The company saw mixed Q3 financial results, with revenue up but remaining unprofitable, and recent insider stock sales by COO Warren Stone and EVP Alicia Olivo. Institutional investors have adjusted their positions, and the stock is currently trading around $12.38.
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
NeoGenomics, Inc. will release its fourth quarter and full year 2025 financial results before the U.S. financial markets open on Tuesday, February 17, 2026. Following the release, company management will host a webcast and conference call at 8:30 a.m. ET to discuss the financial outcomes and recent highlights. The webcast will be accessible via their investor relations website, with a replay available afterward.
Should NeoGenomics’ CFO Transition and Early 2025 Revenue Signals Require Action From NEO Investors?
NeoGenomics, Inc. announced a CFO transition with Abhishek Jain succeeding Jeff Sherman post-2025 year-end audit, coupled with preliminary 2025 revenue guidance projecting double-digit year-over-year growth. While these developments offer insights into evolving management and operations, the core investment case still hinges on the oncology testing platform's ability to scale into a profitable business despite current losses and a high valuation. The article suggests that while the new CFO and revenue guidance are positive, significant challenges regarding execution, pricing, and cost discipline remain, with fair value estimates from the Simply Wall St Community varying widely.
Don't Ignore The Insider Selling In NeoGenomics
NeoGenomics' President & COO, Warren Stone, recently sold shares worth US$277k, representing 15% of his holding. While insiders bought more shares overall in the last year than they sold, this significant sale below the current market price raises questions. Despite the selling, insiders still hold a reasonable 1.3% stake in the company.
Don't Ignore The Insider Selling In NeoGenomics
The article highlights recent insider selling at NeoGenomics, Inc. (NASDAQ:NEO), specifically by President & COO Warren Stone, who sold US$277k worth of stock, representing 15% of his holdings. While there has been more insider buying than selling over the past year in total, this significant sale raises an eyebrow regarding the company's valuation. The author suggests that despite insider selling, NeoGenomics does have reasonable insider ownership, indicating some alignment with shareholders.
Don't Ignore The Insider Selling In NeoGenomics
NeoGenomics' President & COO recently sold US$277k worth of stock, representing 15% of their holding. While insiders bought more shares than they sold over the past year in aggregate, a recent sale below the current market price raises a cautious flag for investors, though insider ownership still suggests good alignment.
Neogenomics pres. Stone sells $277k in NEO stock By Investing.com
Warren Stone, President & Chief Operating Officer of Neogenomics Inc (NASDAQ:NEO), sold 22,128 shares of common stock for $276,681. Post-transaction, Stone directly owns 121,631 shares and holds various stock options and restricted stock units. Neogenomics, with a $1.65 billion market cap, also anticipates Q4 2025 revenue of $190 million, announced leadership changes, and noted a patent case victory.
Neogenomics pres. Stone sells $277k in NEO stock By Investing.com
Warren Stone, President & Chief Operating Officer of Neogenomics Inc (NASDAQ:NEO), sold 22,128 shares of common stock for approximately $276,681. The transaction took place on January 20, 2026, at $12.5037 per share, leaving Stone with 121,631 directly owned shares and various stock options. This sale follows recent positive news for NeoGenomics, including anticipated revenue increases, leadership appointments, and a favorable patent case ruling against Natera.
Neogenomics pres. Stone sells $277k in NEO stock
Warren Stone, President & COO of Neogenomics Inc (NASDAQ:NEO), sold 22,128 shares of common stock for $276,681. This transaction occurred on January 20, 2026, and leaves Stone with 121,631 directly owned shares, in addition to various stock options and restricted units. Neogenomics, with a $1.65 billion market cap, is preparing for its next earnings report on February 25, 2026, and has recently seen positive analyst price target adjustments, leadership changes, and a favorable outcome in a patent dispute.
NeoGenomics (NASDAQ:NEO) COO Sells 22,128 Shares of Stock
NeoGenomics (NASDAQ:NEO) COO Warren Stone sold 22,128 shares of the company's stock for $276,600, reducing his stake by 15.39%. The medical research company recently reported quarterly EPS of $0.03, slightly beating estimates, and revenue growth of 12% year-over-year, though it maintains negative net margins and return on equity. Analysts currently have a consensus "Hold" rating for NEO, with an average price target of $12.00.
Neogenomics pres. Stone sells $277k in NEO stock By Investing.com
Warren Stone, President & COO of Neogenomics Inc (NASDAQ:NEO), sold 22,128 shares of common stock for approximately $277,000 on January 20, 2026. Following the sale, Stone directly owns 121,631 shares and holds various stock options, performance stock units, and restricted stock units. The article also provides recent company news, including Q4 2025 revenue projections, leadership changes, resolution of a patent case, and analyst price target adjustments.
How NeoGenomics’ (NEO) CFO Transition and Double‑Digit Revenue Guidance Has Changed Its Investment Story
NeoGenomics recently announced a CFO transition to Abhishek Jain, effective March 2, 2026, alongside preliminary 2025 revenue guidance of $190 million for Q4 and $727 million for the full year, indicating double-digit growth. This leadership change and revenue outlook prompt questions about balancing financial discipline with expansion in oncology diagnostics. The article suggests investors should focus on the company's ability to translate increased test volumes into efficient use of its fixed cost base despite ongoing losses and a relatively high valuation.
NeoGenomics (NASDAQ:NEO) Raised to Strong-Buy at Zacks Research
Zacks Research has upgraded NeoGenomics (NASDAQ:NEO) to a "Strong-Buy" rating, while the MarketBeat consensus remains a "Hold" with an average target price of $12. The upgrade follows NeoGenomics' preliminary Q4 revenue of $190 million and FY2025 guidance of around $727 million, indicating expected double-digit revenue growth and potential margin improvement. The company also recently appointed Abhishek Jain as CFO and beat quarterly EPS estimates.
NeoGenomics names incoming CFO amid revenue growth
NeoGenomics Inc., an oncology diagnostics company, announced that Abhishek Jain will become its new CFO on March 2, succeeding Jeff Sherman who is retiring. The company also reported preliminary Q4 2025 revenue of approximately $190 million, an 11% increase year-over-year, and full-year 2025 revenue of about $727 million, up 10%.
NeoGenomics, Inc. (NEO) Stock Analysis: Assessing A 16.59% Potential Upside
NeoGenomics, Inc. (NEO) shows a potential upside of 16.59% based on recent analyst ratings, despite current profitability challenges such as a negative EPS and ROE. The company, a key player in cancer-focused diagnostics, exhibits strong revenue growth and positive technical indicators, suggesting a bullish outlook for investors balancing intrinsic growth against high forward P/E.
NeoGenomics forecasts 11% revenue growth for Q4 2025, names new CFO
NeoGenomics announced it expects an 11% year-over-year revenue increase for Q4 2025, reaching approximately $190 million, and projects full-year 2025 revenue of about $727 million. The company also appointed Abhishek Jain as its new CFO, succeeding Jeff Sherman, who will retire in April 2026. These positive financial projections and leadership changes follow strong Q3 2025 earnings and a favorable ruling in a patent dispute.
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
NeoGenomics announced preliminary unaudited revenue for the fourth quarter and full-year 2025, expecting approximately $190 million for Q4 and $727 million for the full year, representing 11% and 10% year-over-year growth, respectively. The company also announced a CFO transition, with Abhishek Jain joining as Executive Vice President on January 12, 2026, and succeeding Jeff Sherman as CFO on March 2, 2026, upon Mr. Sherman's retirement. These financial results are preliminary and subject to change upon completion of the year-end audit.
